Winnow Therapeutics

Winnow Therapeutics is a biotechnology company focused on developing next-generation precision medicines by targeting the ubiquitin-proteasome system (UPS). Launched by Apple Tree Partners (ATP), the company utilizes a proprietary platform to discover and develop small molecule molecular glues and other degraders that recruit E3 ligases to eliminate disease-causing proteins. Their approach aims to expand the druggable proteome by identifying novel E3 ligase-substrate pairs across various therapeutic areas, including oncology, immunology, and neurology. Winnow's technology enables the systematic mapping of the E3 ligase landscape to create highly selective therapies for genetically defined patient populations. The company is currently in the discovery and pre-clinical stages of development, leveraging deep expertise in protein degradation and ligase biology.